SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-21-026167
Filing Date
2021-11-10
Accepted
2021-11-10 16:26:55
Documents
14
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20211110_8k.htm   iXBRL 8-K 26954
2 EXHIBIT 99.1 ex_305547.htm EX-99.1 108205
  Complete submission text file 0001437749-21-026167.txt   279124

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA navb-20211110.xsd EX-101.SCH 3594
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20211110_def.xml EX-101.DEF 11425
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20211110_lab.xml EX-101.LAB 15311
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20211110_pre.xml EX-101.PRE 11585
7 EXTRACTED XBRL INSTANCE DOCUMENT navb20211110_8k_htm.xml XML 2572
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 211397077
SIC: 2835 In Vitro & In Vivo Diagnostic Substances